To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at For Technical questions please contact Thank you.

Privacy Policy Update

We remain dedicated to protecting your data and experience throughout our platforms. We have updated our Privacy Policy and your continued use of the Site means you have accepted the revised Privacy Policy. View now >

Primary Coronary Artery Smooth Muscle Cells; Normal, Human (HCASMC) (ATCC® PCS-100-021)

Organism: Homo sapiens, human  /  Tissue: Coronary artery  /  Cell Type: Myocyte

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue Coronary artery
Cell Type Myocyte
Morphology Elongated and sometimes triangular in shape
Growth Properties adherent
Biosafety Level 1

[These primary cells are not known to harbor an agent recognized to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. Cells derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens.  

ATCC recommends that appropriate safety procedures be used when handling all primary cells and cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures are provided in Laboratory Safety: Principles and Practice, 2nd ed. (ASM Press, Washington, DC) (Fleming et al., 1995) and Caputo, J.L. Biosafety procedures in cell culture. (1988) J. Tissue Culture Methods 11:223.

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online at]

Human Material Precaution 

All tissues used for isolation are obtained under informed consent and conform to HIPAA standards to protect the privacy of the donor’s personal health information. It is best to use caution when handling any human cells. We recommend that all human cells be accorded the same level of biosafety consideration as cells known to carry HIV. With infectious virus assays or viral antigen assays, even a negative test result may leave open the possible existence of a latent viral genome.

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease Normal
Age Batch-specific
Gender Batch-specific
Ethnicity Batch-specific
Arteriolosclerosis, hypertension, arterial disease, organ-specific drug screening, vascular wound healing, tissue remodeling, vascular differentiation, apoptosis, stent development.
Product Format frozen 1 mL
Storage Conditions -130°C or below

The HCASMC cells are cryopreserved in the second passage to ensure the highest viability and plating efficiency.

A complete solution to propagate Vascular Smooth Muscle Cells in low serum conditions.
Complete Growth Medium
  1. Obtain one growth kit from the freezer; make sure that the caps of all components are tight.
  2. Thaw the components of the growth kit just prior to adding them to the basal medium. It is necessary to warm the L-glutamine component in a 37°C water bath and shake to dissolve any precipitates prior to adding to the basal medium.
  3. Obtain one bottle of Vascular Cell Basal Medium (475 mL) from cold storage.
  4. Decontaminate the external surfaces of all growth kit component vials and the basal medium bottle by spraying them with 70% ethanol.
  5. Using aseptic technique, and working in a laminar flow hood or biosafety cabinet, transfer the volume of each growth kit component, as indicated in either Table 1 or 2, to the bottle of basal medium using a separate sterile pipette for each transfer.
  6. Table 1. Vascular Smooth Muscle Cell Growth Kit Components



    Final Concentration

    rh FGF-basic

    0.5 mL

    5 ng/mL

    rh Insulin

    0.5 mL

    5 µg/mL

    Ascorbic acid

    0.5 mL

    50 µg/mL


    25.0 mL

    10 mM

    rh EGF

    0.5 mL

    5 ng/mL

    Fetal Bovine Serum

    25.0 mL



    Antimicrobials and phenol red are not required for proliferation but may be added if desired. The recommended volume of either of the optional components (GA solution or PSA solution) to be added to the complete growth media is summarized in Table 2.

    Table 2. Addition of Antimicrobials/Antimycotics and Phenol Red (Optional)



    Final Concentration

    Gentamicin-Amphotericin B Solution

    0.5 mL

    Gentamicin: 10 µg/mL

    Amphotericin B: 0.25 µg/mL

    Penicillin-Streptomycin-Amphotericin B Solution

    0.5 mL

    Penicillin: 10 Units/mL

    Streptomycin: 10 µg/mL

    Amphotericin B: 25 ng/mL

    Phenol Red

    0.5 mL

    33 µM

  7. Tightly cap the bottle of complete growth medium and swirl the contents gently to assure a homogeneous solution. Do not shake forcefully to avoid foaming. Label and date the bottle.
  8. Complete growth media should be stored in the dark at 2°C to 8°C (do not freeze). When stored under these conditions, complete growth media is stable for 30 days.
  1. Passage normal vascular smooth muscle cells when culture has reached approximately 80% confluence.
  2. Warm both the Trypsin-EDTA for Primary Cells (ATCC PCS-999-003) and the Trypsin Neutralizing Solution (ATCC PCS-999-004) to room temperature prior to dissociation. Warm complete growth medium to 37°C prior to use with the cells.
  3. For each flask, carefully aspirate the spent media without disturbing the monolayer.
  4. Rinse the cell layer two times with 3 to 5 mL D-PBS (ATCC 30-2200) to remove residual traces of serum.
  5. Add pre-warmed trypsin-EDTA solution (1 to 2 mL for every 25 cm2) to each flask.
  6. Gently rock each flask to ensure complete coverage of the trypsin-EDTA solution over the cells, and then aspirate the excess fluid off of the monolayer.
  7. Observe the cells under the microscope. When the cells pull away from each other and round up (typically within 1 to 3 minutes), remove the flask from the microscope and gently tap it from several sides to promote detachment of the cells from the flask surface.
  8. When the majority of cells appear to have detached, quickly add an equal volume of Trypsin Neutralizing Solution (ATCC PCS-999-004) to each flask. Gently pipette or swirl the culture to ensure all of the trypsin-EDTA solution has been neutralized.
  9. Transfer the dissociated cells to a sterile centrifuge tube and set aside while processing any remaining cells in the flask.
  10. Add 3 to 5 mL D-PBS (ATCC 30-2200) to the flask to collect any additional cells that might have been left behind.
  11. Transfer the cell/D-PBS suspension to the centrifuge tube containing the trypsin-EDTA-dissociated cells.
  12. Repeat steps 10 and 11 as needed until all cells have been collected from the flask.
  13. Centrifuge the cells at 150 x g for 3 to 5 minutes .
  14. Aspirate the neutralized dissociation solution from the cell pellet and resuspend the cells in 2 to 8 mL fresh, pre-warmed, complete growth medium.
  15. Count the cells and seed new flasks at a density between 2,500 and 5,000 cells per cm2.
  16. Place newly seeded flasks in a 37°C, 5% CO2, incubator for at least 24 to 48 hours before processing the cells further. Refer to Maintenance for guidelines on feeding.
Volume 1 mL
Cells per Vial One vial contains a minimum of 5 x 105  viable cells.
Sterility Tests
Bacteria and Yeast: Negative
Mycoplasma: Negative
Viral Testing
Hepatitis B: Negative
Hepatitis C: Negative
HIV-1: Negative
Viability ≥ 70% when thawed from cryopreservation.
Population Doubling Capacity ≥ 15 in complete growth medium
C of A
Certificate of Analysis
Certificate of Analysis
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation

Amreddy N, et al. Tumor-Targeted and Ph-Controlled Delivery of Doxorubicin Using Gold Nanorods for Lung Cancer Therapy. Int J Nanomedicine 10:6773-88, 2015. PubMed: 26604751

Cole C, et al. Arum Palaestinum with Isovanillin, Linolenic Acid and b-Sitosterol Inhibits Prostate Cancer Spheroids and Reduces the Growth Rate of Prostate Tumors in Mice. BMC Complement Altern Med 15:264, 2015. PubMed: 26243305

Song Y, et al. Effects of Integrin a5b1 on the Proliferation and Migration of Human Aortic Vascular Smooth Muscle Cells. Mol Med Rep 2(13):1147-55, 2016. PubMed: 26648324

Song J, et al. Association of Serum Phospholipid Pufas with Cardiometabolic Risk: Beneficial Effect of Dha on the Suppression of Vascular Proliferation/Inflammation. Clin Biochem 6(47):361-8, 2014. PubMed: 24457065

Vadivelu RK, et al. Betulinic Acid Inhibits Growth of Cultured Vascular Smooth Muscle Cells in Vitro by Inducing Arrest and Apoptosis. Evid Based Complement Alternat Med 2012:251362, 2012. PubMed: 23056140

Aguilar HN, et al. Rho-Kinase Mediates Diphosphorylation of Myosin Regulatory Light Chain in Cultured Uterine, but Not Vascular Smooth Muscle Cells. J Cell Mol Med 12(16):2978-89, 2012. PubMed: 22947248

Elcin AE, et al. Differential Gene Expression Profiling of Human Adipose Stem Cells Differentiating into Smooth Muscle-Like Cells by TGFb1/BMP4. Exp Cell Res 2(352):207-17, 2017. PubMed: 28185836

Laberge RM, et al. Treatment for osteoarthritis by intra-articular administration of cis-imidazoline. United States Patent Pat. No.: US 9,855,266 B2, 2018.

Laberge RM, et al. Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells. United States Patent Pat. No.: US 9,849,128 B2, 2017.